Nastech gets grant to develop small-interfering RNA therapeutics to treat influenza

By Elaine Rigoli

Tampa, Fla., Aug. 29 - Nastech Pharmaceutical Co., Inc. said the National Institute of Allergy and Infectious Diseases, a division of the National Institutes of Health, awarded the company a phase 1 small business innovation research grant.

The company will use this award to further develop its small-interfering RNA therapeutics to prevent and treat influenza.

Influenza infects 5% to 15% of the world's population in a typical year, resulting in 250,000 to 500,000 deaths, according to the World Health Organization.

Additional grants for program funding are still pending.

Nastech is developing small-interfering RNA therapeutics that specifically target conserved regions of the influenza viral genome and are based on intellectual property obtained in February from the acquisition of Galenea Corp.

Nastech is a pharmaceutical company located in Bothell, Wash.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.